학술논문

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
Document Type
Article
Source
In: Blood. (Blood, 25 November 2021, 138(21):2031-2041)
Subject
Language
English
ISSN
15280020
00064971